Bioquell Regulatory News (BQE)

RNS Number : 3120S

Bioquell PLC

08 September 2010

 

 

 

8 September, 2010

 

 

Bioquell PLC

£3.6m CBRN filtration contract award

 

Bioquell PLC (LSE: BQE) - provider of specialist low temperature, residue-free bio-decontamination technologies to the healthcare, life sciences and defence sectors - announces that it has been awarded a £3.6m defence contract relating to the supply of CBRN filtration systems to an existing Middle Eastern customer. Substantially all of this contract is anticipated to be invoiced in 2011.

 

Commenting on this contract award, Nick Adams, Group Chief Executive of Bioquell PLC, said:

"We are delighted to have won a significant CBRN filtration system contract from a long-standing overseas customer"

 

- Ends -

 

 

Enquiries:

 

Bioquell PLC 01264 835 900

Nick Adams Group Chief Executive

Mark Bodeker Chief Operating Officer / Finance Director

 

 

Notes to editors:

§ Bioquell is a UK-headquartered, international technology company with two divisions:

o Bio-decon which sells specialist bio-decontamination products and services into the Healthcare, Life Sciences and Defence sectors, with most of its revenues generated from overseas customers; and

o TRaC which provides specialist Testing, Regulatory and Compliance services, which are largely governed by regulations, to UK corporates.

§ Bioquell's bio-decontamination technology is principally based around hydrogen peroxide vapour - which is highly efficacious at eradicating micro-organisms such as bacteria and viruses at room temperature - and is subsequently broken down using specialist catalysts to water vapour and oxygen at the end of the bio-decontamination process.

§ Bioquell's bio-decontamination technology:

o is used to eradicate "superbugs" from hospitals; independent scientific research has demonstrated that 'bioquelling' hospital equipment and facilities reduces the rates of hospital acquired infection;

o is used by bio-pharmaceutical, biotechnology and research institutions to provide sterile equipment and/or sterile working environments;

o has been selected by the United States Department of Defense for the JSSED programme to decontaminate sensitive equipment against biological and chemical warfare agents;

o is used in other sectors where bioburden can create significant problems including, for example, the food industry; and

o also comprises specialist filtration technology including peroxide catalysis and chemical, biological, radiological and nuclear ("CBRN") filtration systems used principally in the defence sector.

§ Bioquell currently has overseas operations in the USA, France, Ireland and Singapore.

§ TRaC sells its specialist services to the product development departments of a broad range of companies, principally based in the UK, with a particular focus on aerospace, military and telecoms clients.

 

This information is provided by RNS

The company news service from the London Stock Exchange